Abpro Bio Co., Ltd. Stock

Equities

A195990

KR7195990007

Industrial Machinery & Equipment

End-of-day quote Korea S.E. 06:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
534 KRW +1.91% Intraday chart for Abpro Bio Co., Ltd. +10.33% -2.02%
Sales 2022 22.11B 16.14M Sales 2023 25.38B 18.52M Capitalization 155B 113M
Net income 2022 -8.14B -5.95M Net income 2023 -25.74B -18.79M EV / Sales 2022 4.73 x
Net cash position 2022 10.89B 7.95M Net cash position 2023 8.07B 5.89M EV / Sales 2023 5.8 x
P/E ratio 2022
-13.9 x
P/E ratio 2023
-5.89 x
Employees 52
Yield 2022 *
-
Yield 2023
-
Free-Float 90.4%
More Fundamentals * Assessed data
Dynamic Chart
Abpro Bio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Abpro Bio Co., Ltd. cancelled the acquisition of 30.911846% stake in Zinitix Co., Ltd. from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim. CI
Abpro Bio Co., Ltd. agreed to acquire 30.911846% stake in Zinitix Co., Ltd. from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion. CI
Abpro Bio Co., Ltd. announced that it has received KRW 5.999999552 billion in funding CI
Abpro Bio Co., Ltd. announced that it expects to receive KRW 4.99999895 billion in funding CI
Abpro Bio Co., Ltd. announced that it has received KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment Arm CI
Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment Arm CI
KUKBO Logistics Co.,Ltd acquired 19.35% stake in Bog International Co., Ltd. from Abpro Bio Co., Ltd. for KRW 2.8 billion. CI
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 16.4999812 billion in funding from Osung Advanced Materials Co., Ltd., Abpro Bio Co., Ltd. CI
Abpro Bio Co., Ltd. announced that it has received KRW 10 billion in funding from Korea Bond Investment Advisory Co., Ltd. CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 16.4999812 billion in funding from Osung Advanced Materials Co., Ltd. and other investors CI
An unknown buyer cancelled the acquisition of 75% stake in UG Asset Co., Ltd. from Abpro Bio Co., Ltd.. CI
Microtech Co.,Ltd cancelled the acquisition of 80% stake in Vitro Corporation from Abpro Bio Co., Ltd. from Abpro Bio Co., Ltd.. CI
Abpro Bio Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Korea Bond Investment Advisory Co., Ltd. CI
Abpro Bio Co., Ltd.(KOSDAQ:A195990) added to S&P Global BMI Index CI
More news
1 day+1.91%
1 week+10.33%
Current month-4.64%
1 month-1.29%
3 months-8.72%
6 months+0.19%
Current year-2.02%
More quotes
1 week
482.00
Extreme 482
570.00
1 month
473.00
Extreme 473
576.00
Current year
464.00
Extreme 464
632.00
1 year
350.00
Extreme 350
940.00
3 years
339.00
Extreme 339
1 710.00
5 years
339.00
Extreme 339
3 400.00
10 years
339.00
Extreme 339
4 883.33
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 -
Chief Executive Officer 52 -
Director/Board Member 47 -
Members of the board TitleAgeSince
Director/Board Member 75 19-12-31
Director/Board Member 56 -
Director/Board Member 47 -
More insiders
Date Price Change Volume
24-04-23 534 +1.91% 728,395
24-04-22 524 +6.72% 1,493,446
24-04-19 491 -1.60% 535,955
24-04-18 499 +2.04% 506,773
24-04-17 489 +1.03% 742,825

End-of-day quote Korea S.E., April 22, 2024

More quotes
Abpro Bio Co., Ltd., formerly Ugint Co., Ltd., is a Korea-based company engaged in machine tools manufacturing. The Company produces and distributes small sized machining centers for notebooks, smart phones, tablet personal computers, mobile phones, base plates, light emitting diode (LED) and light crystal display (LCD) television panels, automobile parts, motorbikes parts and aircraft parts. The Company also engages in original equipment manufacturing business (OEM). The Company operates its business within domestic markets and foreign markets such as China and Europe countries.
More about the company
  1. Stock Market
  2. Equities
  3. A195990 Stock